Skip to main content

Table 1 CLEAR I and CLEAR II RA patient characteristics at the time of enrollment in the registries and stratification by anti-PAD4 and anti-PAD4/PAD3 positivity

From: Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans

  All patients Anti-PAD4-negative (P0) Anti-PAD4 only (P4) Anti-PAD4/PAD3 (XR) P value
Demographic and RA-related variable (N = 192) (N = 146) (N = 26) (N = 20) P4 vs P0 XR vs P0 XR vs P4
Age (years), mean (SD) 55 (12.2) 54 (12.1) 55 (13.9) 59 (8.6) 0.755 0.077 0.288
Female, % 86 85 96 80 0.207 0.523 0.151
Disease duration (years), mean (SD) 8.1 (10.8) 7.2 (10.5) 10.4 (11.2) 12.8 (11.6) 0.029 0.004 0.386
+anti-CCP, % 73 67 88 95 0.035 0.008 0.622
Total radiographic score,a median (IQR) 2 (0–57) 2 (0–11) 2 (1–104) 76 (3–117) 0.231 0.001 0.082
CRP (mg/dl) 14 (36) 16 (40) 8 (10) 9 (13) 1.000 0.391 0.598
Smoking, %      0.387 0.183 0.852
Current 56 33 19 15    
Former 45 21 27 35    
Never 92 46 54 50    
Medications, %
 Methotrexate 63 63 69 85 0.660 0.080 0.302
 HCQ 29 29 34 20 0.645 0.441 0.336
 Sulfasalazine 8 8 8 5 1.000 1.000 1.000
 Leflunomide 5 5 0 5 0.600 1.000 0.435
 Infliximab 4 4 0 10 0.593 0.248 0.184
 Etanercept 4 4 4 10 1.000 0.248 0.572
  1. Categorical variables were tested using Fisher’s exact tests, and continuous variables were tested using Wilcoxon rank sum tests
  2. aTotal joint erosion and joint space narrowing
  3. CLEAR Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis, RA rheumatoid arthritis, PAD peptidyl arginine deiminase enzyme, CRP C-reactive protein, HCQ hydroxychloroquine, IQR interquartile range
  4. P values less than 0.05 are shown in bold